Omnicell (OMCL) is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s Advanced Services offerings is highly encouraging to sustain growth in the upcoming quarters. Efforts to expand into more overseas markets instill optimism. However, adverse macroeconomic challenges and fierce rival pressure could hurt Omnicell’s performance.Currently sporting a Zacks Rank #1 (Strong Buy), OMCL st ...

The market expects Omnicell (OMCL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released ...

Omnicell, Inc. (OMCL) has witnessed strong momentum in the past year. Shares of the company have risen 26.2% against 15.7% decline of the industry. The S&P 500 composite has increased 24.2%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Omnicell develops and markets end-to-end automation solutions for the medication-use process. The company's products enable care providers to improve patient saf ...

Core Viewpoint - Omnicell (OMCL) shows a positive earnings outlook, with analysts raising their earnings estimates, indicating potential for continued stock momentum [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions reflects growing analyst optimism about Omnicell's earnings prospects, which is expected to influence the stock price positively [2]. - The current-quarter earnings estimate is $0.57 per share, representing a 72.73% increase from the previous year, with a 9.57% increase in consensus estimates over the last 30 days [5]. - For the full year, the expected earnings are $1.68 per share, showing a year-over-year decline of 12.04%, but the consensus estimate has increased by 10.67% due to positive revisions [6]. Zacks Rank - Omnicell has achieved a Zacks Rank 1 (Strong Buy), supported by strong agreement among analysts in raising earnings estimates, which historically correlates with stock outperformance [3][7]. - Stocks with Zacks Rank 1 and 2 have shown significant outperformance compared to the S&P 500 [7]. Stock Performance - The stock has gained 6.6% over the past four weeks, driven by solid estimate revisions, suggesting that it may be a good addition to investment portfolios [8].

Omnicell (OMCL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Th ...

Omnicell, Inc. (OMCL) recently introduced OmniSphere, a next-generation, cloud-native software workflow engine and data platform. The new platform is designed to leverage the full power of a cloud-native architecture and seamlessly integrate robotics and smart devices to support more secure, data-driven medication management across the continuum of care. OMCL Stock’s Trend Following the NewsSubsequent to the news, OMCL’s share price moved north marginally by 0.1% to $47.14 Tuesday. Earlier this year, Omnice ...

Omnicell (OMCL) closed the last trading session at $41.82, gaining 4.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $53 indicates a 26.7% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $11.75. While the lowest estimate of $37 indicates a 11.5% decline from the current price level, the most optimistic analyst expects the ...

Omnicell, Inc.'s (OMCL) growth in the third quarter of 2024 can be attributed to the company’s long-term development strategy, driven by innovative solutions, expansion into new markets, strategic partnerships and procurement of new technologies. OMCL is on track to meet its 2025 financial goals, supported by increasing tech services and long-term customer partnerships. Stable solvency buoys optimism. However, a headwind from macroeconomic challenges could adversely impact the company’s performance. In the ...

Omnicell (OMCL) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this Omnicell Inc. Should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions ...

Michael (Mike) Dion is an FP&A, Corporate Finance, and Small Business expert who spent the last 12 years working in the Fortune 100, building a startup's finance and accounting department, advising small businesses, and guiding non-profit organizations as a board member. He has finance experience across multiple industries, including Telecom, Media and Entertainment, Hospitality, and Construction. He founded F9 Finance, a website that helps Finance professionals accelerate their careers; and simplifies Fina ...